PMC6280406_01
PET/CT at the time pazopanib was started. a CT lung window; b CT mediastinal window; c PET; d fusion CT and PET
13569_2018_108_Fig1_HTML.jpg
PMC6280406_01_13569_2018_108_Fig1_HTML.jpg
Fig1
At that time the chest imaging was remarkable for massive infiltration by innumerable lung lesions with very low-background metabolic activity (Figs. 1, 2); of note, patient denied any significant shortness of breath at rest or when walking.  
PET/CT 4 years since pazopanib was started. a CT lung window; b CT mediastinal window; c PET; d fusion CT and PET
13569_2018_108_Fig2_HTML.jpg
PMC6280406_01_13569_2018_108_Fig2_HTML.jpg
Fig2
At that time the chest imaging was remarkable for massive infiltration by innumerable lung lesions with very low-background metabolic activity (Figs. 1, 2); of note, patient denied any significant shortness of breath at rest or when walking.  
PET/CT before (lower images) and after (upper images) palliative radiation therapy to the pelvis
13569_2018_108_Fig3_HTML.jpg
PMC6280406_01_13569_2018_108_Fig3_HTML.jpg
Fig3
A PET/CT done about 4 months after completing radiation therapy showed a metabolic and anatomic response within the pelvic mass (11.8 x 9.2 cm, SUV = 2.8) and the left inguinal area (12.1 x 4.6 cm, SUV = 2.7; Figs. 3, 4).
PET/CT before (lower images) and after (upper images) palliative radiation therapy to the left inguinal/thigh area
13569_2018_108_Fig4_HTML.jpg
PMC6280406_01_13569_2018_108_Fig4_HTML.jpg
Fig4
A PET/CT done about 4 months after completing radiation therapy showed a metabolic and anatomic response within the pelvic mass (11.8 x 9.2 cm, SUV = 2.8) and the left inguinal area (12.1 x 4.6 cm, SUV = 2.7; Figs. 3, 4).